Abstract

The invention relates to novel caging-group-free photoactivatable fluorescent dyes having the structural formula I: The invention relates to novel caging-group-free photoactivatable fluorescent dyes having the structural formula I: The invention relates to novel caging-group-free photoactivatable fluorescent dyes having the structural formula I: as well as to the corresponding photoactivated fluorescent dyes having the structural formula II: The invention relates to novel caging-group-free photoactivatable fluorescent dyes having the structural formula I: as well as to the corresponding photoactivated fluorescent dyes having the structural formula II: The invention relates to novel caging-group-free photoactivatable fluorescent dyes having the structural formula I: as well as to the corresponding photoactivated fluorescent dyes having the structural formula II: The invention further relates to the use of the photoactivatable compounds as such or after photoactivation, in particular as fluorescent tags, analytical reagents and labels in optical microscopy, imaging techniques, protein tracking, nucleic acid labeling, glycan analysis, capillary electrophoresis, flow cytometry or as a component of biosensors, or as analytical tools or reporters in microfluidic devices or nanofluidic circuitry.

IPC Classes  ?

• C09B 57/00 - Other synthetic dyes of known constitution
• C09B 6/00 - Anthracene dyes not provided for above
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

The present invention relates to a method for producing a fat composition comprising the following steps: a) providing water, b) adding lipase, c) adding triglyceride, d) incubate the mixture obtained in step c), e) inactivation of lipase, f) separation of the aqueous phase from the fatty phase of the mixture obtained in step e) in a separating funnel, g) optional heating of the separated fatty phase to remove the remaining aqueous phase, wherein the method is performed without the addition of papain. In addition, the present invention relates to a fat composition obtained by the method according to the invention and a food composition comprising the fat composition according to the invention, as well as method for producing the food composition.

IPC Classes  ?

• A23L 13/60 - Comminuted or emulsified meat products, e.g. sausagesReformed meat from comminuted meat product
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• C11B 1/00 - Production of fats or fatty oils from raw materials
• C11C 3/10 - Ester interchange
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats

Abstract

The present invention relates to methods for modifying the activity of transcription factors by altering the periodicity and/or number of the aromatic amino acid residues in their intrinsically disordered regions (IDRs) thereby obtaining altered transcription factors having modified, e.g., increased and/or reduced transcriptional activity. Further, the present invention relates to novel altered transcription factors and nucleic acid molecules encoding those altered transcription factors. Furthermore, applications for the altered transcription factors, e.g., in cell programming methods, are disclosed.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The invention discloses a method that uses a measured density map of a molecule and related molecular model to improve the resolution of the molecule structure using fitness scores between conformers of models of the unresolved parts of the molecule and the density map.

IPC Classes  ?

• G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR

Abstract

The present invention relates to a method for increasing the photosynthesis of a plant, plant part, or plant cell by increasing the expression of the squamosa promoter binding protein-like gene 9 (SPL9 gene) in the plant, plant part, or plant cell and/or by increasing the level of the squamosa promoter binding protein-like protein 9 (SPL9 protein) in the plant, plant part, or plant cell.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 9/22 - Ribonucleases
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A potential measuring apparatus (100) for determining a physicochemical surface property based on a surface potential at a sample surface (2) of a solid sample (1), like the surface potential and/or a zeta potential of the sample surface (2), comprises a sample support (10) for accommodating the sample (1), a drop supply device (20) for placing a liquid probe drop (3) on the sample surface (2), a drop movement device (30) for providing a sliding movement of the probe drop (3) along a predetermined sliding path (4) on the sample surface (2), an electrode measuring device (40) for sensing an electrical quantity including at least one of a drop voltage and a drop charge of the probe drop (3) after passing the sliding path (4), wherein the electrode measuring device (40) includes a probe electrode (41) arranged at a downstream end of the sliding path 4 and a measuring circuit (42) coupled with the probe electrode (41), and a calculation device (50) for determining the physicochemical surface property based on the electrical quantity. Furthermore, a potential measuring method for determining a physicochemical surface property based on a surface potential at a sample surface (2) of a solid sample (1) is described.

IPC Classes  ?

• G01N 13/02 - Investigating surface tension of liquids
• G01N 27/60 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrostatic variables
• G01R 31/26 - Testing of individual semiconductor devices

Abstract

Method for automatic focusing and astigmatism correction for a specific microscope setup, in particular an electron microscope, the microscope being at least adjustable in microscope parameters a working distance, a stigmator in a x-direction and a stigmator in a y-direction, the method comprising the steps: a) capturing a first image of a sample with a first working distance perturbation and capturing a second image of the sample with a second working distance perturbation around a current working distance and current stigmator settings; b) selecting n subareas of the first image and n subareas of the second image, n≥1, wherein an i-th subarea of the first image and an i-th subarea of the second image form an i-th input patch pair, 1≤i≤n; c) processing each i-th input patch pair and receiving an i-th correction term comprising a correction to the current working distance, stigmator in x-direction and stigmator in y-direction; d) receiving an output correction term as a function of all the correction terms; e) adjusting the current working distance and stigmator settings by applying the output correction term to the current working distance and stigmator settings.

IPC Classes  ?

• H01J 37/21 - Means for adjusting the focus
• H01J 37/153 - Electron-optical or ion-optical arrangements for the correction of image defects, e.g. stigmators

Abstract

Provided are a method and a device for characterizing a resonator element, a method and a device for providing an optical frequency reference, a LIDAR system and a gas sensing system. The method includes coupling a laser light into the resonator element, the resonator element having multiple carrier resonances for the carrier frequency of the laser light.

IPC Classes  ?

• G01M 11/02 - Testing optical properties

Abstract

The invention relates to a source arrangement (10) for a TLE system (100) for providing a source element (12) comprising or consisting of a source material (14) to be evaporated and/or sublimated by a laser beam (112), comprising a support (20) carrying said source element. Further, the invention relates to a TLE system (100) comprising a laser source (110) for providing a laser beam (112), a reaction chamber (120) for containing a reaction atmosphere (124), a source arrangement (10) for providing a source element (12) comprising or consisting of a source material (14) to be evaporated and/or sublimated by the laser beam (112) within the reaction chamber (120), and a substrate arrangement (130) for providing a substrate (132) to be coated within the reaction chamber (120) with the evaporated and/or sublimated source material (14). In addition, the invention relates to a method for using a TLE system (100), the TLE system (100) comprising a laser source (110) for providing a laser beam (112), a reaction chamber (120) for containing a reaction atmosphere (124), a source arrangement (10) for providing a source element (12) comprising or consisting of a source material (14) to be evaporated and/or sublimated by the laser beam (112) within the reaction chamber (120), and a substrate arrangement (130) for providing a substrate (132) to be coated within the reaction chamber (120) with the evaporated and/or sublimated source material (14).

IPC Classes  ?

• C23C 14/28 - Vacuum evaporation by wave energy or particle radiation

Abstract

The present disclosure relates to compounds that bind to the kelch domain-containing protein 2 (KLHDC2) E3 ligase active site and heterobifunctional targeted protein degraders comprising the compounds. Methods of using these degraders in the treatment of cancer is also described. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• C07D 495/14 - Ortho-condensed systems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Connectomes of human cortical gray matter require high-contrast homogeneously stained samples sized at least 2-3 mm on a side, and a whole-mouse brain connectome requires samples sized at least 5-10 mm on a side. Here, en-bloc staining and postprocessing protocols are reported, including dehydrating and embedding of neuronal samples, for dense neuronal circuit reconstruction and other applications.

IPC Classes  ?

• G01N 1/30 - StainingImpregnating
• G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]

Abstract

The present invention relates to multifunctional agents as defined in the claims based on N-substituted 1,4-benzothiazepines with cyclopropanol groups and their "open" analogues (such as the 3-[(4-methoxyphenyl)oxy]- and 3-[(4-5 methoxyphenyl)thio]propane-1-amine cyclopropanol derivatives; see formulae below) as well as the rearrangement products obtained from such cyclopropanol compounds, i.e. ethyl ketones, and the oxidation products from such cyclopropanol compounds, i.e. oxiranes. Such compounds can be used by preventing Ca2+ leak through ryanodine receptor 2 (RyR2) and enhance cardiac sarco-endoplasmic reticulum (SR) Ca2+ load by activation of Ca2+-dependent ATPase 2a (SERCA2a) for example for the treatment of cardiac or neuronal diseases.

IPC Classes  ?

• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/06 - Antiarrhythmics
• A61P 25/00 - Drugs for disorders of the nervous system
• C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
• C07C 217/20 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
• C07C 319/20 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
• C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07D 281/10 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Abstract

The present invention relates to a process for preparing diamond particles, comprising subjecting a nanodiamond precursor material to a pressure of at least 8 GPa and a temperature of at least 900°C, wherein the diamond precursor material comprises a polycyclic aromatic compound which contains from 10 to 200 fused six-membered aromatic rings.

IPC Classes  ?

• C01B 32/26 - Preparation
• B01J 3/06 - Processes using ultra-high pressure, e.g. for the formation of diamondsApparatus therefor, e.g. moulds or dies

Abstract

The present invention relates to nucleic acids providing new-to-nature target sites for site-directed nucleases (landing pads) and methods to generate and use the same. Furthermore, the elements for generating said nucleic acids, namely underrepresented sequences/sequence fragments in one or more reference genome and protospacers are provided as well as methods to generate said elements. The invention also provides genomes and cells comprising the nucleic acids (landing pads).

IPC Classes  ?

• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to proteins or polypeptides involved in fatty acid synthesis, such as fatty acid synthase (FAS). Said protein comprises one or more polypeptide chains wherein said polypeptide chains comprises one or more subunits having at least one amino acid substitution as defined resulting in altered activity of fatty acid synthesis. The present invention relates further to nucleic acid molecules encoding the proteins or the polypeptide domains as well to host cells containing said nucleic acid molecules, e.g. in form of vectors. The present invention describes further a method for production of fatty acids comprising the cultivation of the host cells according to the present invention as well as the use of the protein according to the present invention or the nucleic acid according to the present invention or the host cell according to the present invention for the production of biofuels, the production of fine chemicals, flavoring compounds, the determination of fungicides and actinobacterial biocides. Moreover, in silico methods are described allowing the identification of molecules capable of selectively altering the activity of an enzymatic domain present in the FAS or altering a step of fatty acid synthesis by FAS I comprising determining and modelling molecules interacting under physiological conditions with at least one amino acid in a protein as defined herein. Further, a method of identifying a compound capable of altering at least one of the enzymatic activities of FAS is provided including the step of bringing into contact a candidate compound with the FAS as defined herein and determining whether said candidate demonstrates any interaction with the FAS. Finally, a protein is provided, namely, a mutated ACP which results in alteration of FAS activity.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12P 7/6409 - Fatty acids
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil

Abstract

The present invention relates to method of treating a patient suffering from a gastrointestinal stromal tumor (GIST), comprising administering to said patient a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Furthermore, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a gastrointestinal stromal tumor (GIST) in a patient.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an underwater apparatus for sampling and to a related method for sampling in situ water flows in a body of water.

IPC Classes  ?

• G01N 1/14 - Suction devices, e.g. pumpsEjector devices
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state

Abstract

The present invention relates to a method for expanding liver cells, wherein the method comprises (a) expanding the liver cells within an extracellular matrix in an expansion medium, wherein the expansion medium comprises a Wnt surrogate or activator and an inhibitor of the Hippo signalling pathway, and preferably with the proviso that the expansion medium does not comprise nicotinamide.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/407 - LiverHepatocytes

Abstract

The present invention relates to a method for releasing macromolecules from one or more living cells comprising (a) flattening the one or more living cells between two surfaces such that the membrane of the living cells becomes permeable or becomes more permeable for the macromolecules, wherein the surfaces that face the cells are functionalized by an antifouling coating that comprises biocompatible polymeric brushes, and (b) incubating the one or more fattened cells, wherein the macromolecules are released from the one or more living cells.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The present invention relates to a method for the introduction of macromolecules and/or particles into living cells comprising (a) flattening the living cells between two surfaces such that the cells become amenable for the uptake of the macromolecules and/or particles, wherein the surfaces that face the cells are functionalized by an antifouling coating that comprises biocompatible polymeric brushes, and (b) incubating the fattened cells, wherein the macromolecules and/or particles become introduced into the cells.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/33 - Disintegrators
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

The present application relates to: an imaging device for telecentric imaging of a plurality of light beams into a target area; and an associated micromirror device. The imaging device comprises a beam tilt correction element and a beam control device which is designed to image N >= 2 substantially non-overlapping light beams onto the beam tilt correction element and to control a position of one or more of the N light beams on the beam tilt correction element. The imaging device also comprises a beam imaging device which is designed to image the light beams corrected by the beam tilt correction element onto the target area, wherein the beam tilt correction element is designed to correct a tilt of each of the N light beams such that the N light beams are imaged onto substantially non-overlapping positions in the target area. The beam tilt correction element may be implemented, for example, using a micromirror device.

IPC Classes  ?

• G02B 27/10 - Beam splitting or combining systems
• G02B 26/08 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the direction of light
• G02B 26/12 - Scanning systems using multifaceted mirrors

Abstract

The present invention relates to a method for flattening living cells, comprising (a) flattening the cells between two microscopy slides, wherein the surfaces of the microscopy slides that face the cells are functionalized by an antifouling coating that comprises biocompatible polymeric brushes.

IPC Classes  ?

• G01N 1/30 - StainingImpregnating
• G06T 7/00 - Image analysis
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to CoA-independent reductive aldolases derived from ene reductases (ERs) for preparing α-branched β'-hydroxy carbonyl compounds through enzymatic-catalyzed reductive aldol reaction by reacting α,β-unsaturated carbonyl donors with carbonyl acceptors in the presence of a polypeptide capable of catalyzing reductive CoA-independent aldol reactions and a cofactor, wherein the polypeptide is a modified ene reductase (ER). The present invention further relates to a method for preparing α-branched β'-hydroxy carbonyl compounds through enzymatic-catalyzed reductive aldol reaction.

IPC Classes  ?

• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group

Abstract

The present invention relates to compounds, compositions and kits suitable to precise genome editing efficiency in a eukaryotic target organism.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 33/243 - PlatinumCompounds thereof
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/20 - Interleukins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a polypeptide with at least 85% sequence identity to SEQ ID NO: 1, as an endo-β-1,4-xylanase (EC 3.2.1.8) having transglycosylation activity. Preferably, said polypeptide is obtained from Rhamnusium bicolor. In another aspect, the present invention refers to a polynucleotide encoding said polypeptide, a preparation method of said polypeptide, use of said polypeptide for producing xylose oligosaccharides by transglycosylation reaction, and a producing method of xylose oligosaccharides by using said polypeptide. Furthermore, the present invention is directed to a mixture of xylose oligosaccharides obtainable by the producing method by using said polypeptide, and use of the mixture of said xylose oligosaccharides in life science, in particular, as prebiotics, nutraceuticals, pharmaceutically active ingredients, or food supplements.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12P 19/02 - Monosaccharides

Abstract

The present invention relates to a catalytically active material, the preparation thereof, and the use of the catalytically active material, e.g. in the catalytic hydrogenation of CO2 to methanol. The catalytically active material comprising a metal oxide doped with a doping metal, wherein the metal oxide is selected from CeO2, ZnO, Ga2O3, In2O3, ZrO2, Fe2O3 and Al2O3, the doping metal is selected from Cu, Rd and Au, and the catalytically active material is obtainable by a method comprising a step of non-thermal plasma treatment.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 35/45 - Nanoparticles
• B01J 35/58 - Fabrics or filaments
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/08 - Heat treatment
• B01J 37/12 - Oxidising
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Goods & Services

Education, providing of training, cultural activities. Research services.

Abstract

The invention relates to nanofilament-coated membranes with hierarchical porous structures comprising a microporous polymer support membrane having through-going pores with a nominal pore diameter in the range from 0.2 μm to 50 μm and a superhydrophobic fluorine-free nanoporous layer having through-going pores with a nominal pore diameter in the range from 5 nm to 200 nm provided on said support membrane and comprising or consisting of a porous network of polysiloxane nanofilaments. In more specific embodiments of said nanofilament-coated porous membranes, the microporous support membrane comprises or consists of a polymer which is selected from the group consisting of polyethersulfone (PES), cellulose acetate (CA), polypropylene (PP), polyamide (nylon), polytetrafluoroethylene (PTFE), polyvinyl difluoride (PVDF) or polyethylene (PE). A second aspect of the invention relates to the use of these nanofilament-coated porous membranes for membrane distillation, in particular in a process of desalination of saline or distillation of contaminated water or extraction of water from waste water or extraction of other volatile components from a feed solution and to a device, in particular a membrane distillation device, comprising these nanofilament-coated porous membranes. A further aspect of the invention relates to a method for preparing these nanofilament-coated porous membranes.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 61/36 - PervaporationMembrane distillationLiquid permeation
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 69/10 - Supported membranesMembrane supports
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

The present invention refers to a coating apparatus for coating a substrate of a substrate material with at least one material layer of a layer material, said coating apparatus comprising a process chamber having a process volume for receiving a substrate holder for arranging the substrate, wherein the substrate holder is arranged in a fixed position in the process volume such that the substrate holder can furthermore be provided rotatable and/or movable essentially in a plane normal to the deposition direction as a whole, wherein the process chamber has a chamber wall for at least substantially completely enclosing the process volume; a gas system connected in a fluid-communicating manner to the process volume for generating a coating atmosphere in the process volume; and a source holder arranged in the process volume and providing at least one source material.

IPC Classes  ?

• C23C 16/48 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating by irradiation, e.g. photolysis, radiolysis, particle radiation
• C23C 16/40 - Oxides
• C23C 16/458 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for supporting substrates in the reaction chamber

Abstract

A method of determining a dimensional parameter of a microstructured optical fiber (MOF), the method comprising: directing radiation towards the MOF; obtaining one or more signals associated with interference of the radiation between structural elements of the MOF; determining a distance between the structural elements based on the one or more signals associated with interference of the radiation between structural elements of the MOF; and determining the dimensional parameter based on the determined distance. A method for obtaining a MOF is also described.

IPC Classes  ?

• G02B 6/02 - Optical fibres with cladding
• G02B 6/032 - Optical fibres with cladding with non-solid core or cladding

Abstract

The invention relates to a method for the controlled deposition of a nitride layer (80) of a target nitride (82) on a substrate (70) in a thermal laser epitaxy (TLE) system (100), the target nitride (82) comprising a defined stoichiometry and being formed from one or more evaporated and/or sublimated source materials and nitrogen originating from a gaseous nitridizing agent (54), the TLE system (100) further comprising a reaction chamber (10) and one or more laser sources (20) for providing laser beams (22) within the reaction chamber (10). Further, the invention relates to a TLE system (100) constructed for carrying out said method.

IPC Classes  ?

• C23C 14/00 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/28 - Vacuum evaporation by wave energy or particle radiation
• C23C 14/54 - Controlling or regulating the coating process
• C30B 23/06 - Heating of the deposition chamber, the substrate, or the materials to be evaporated
• C30B 29/40 - AIIIBV compounds

Abstract

The present invention relates to an Poly(ADP-Ribose) Polymerase 1 (PARP-1) inhibitor and/or an immune checkpoint inhibitor for the treatment of cancer in a subject that overexpresses Ubiquilin 1 (UBQLN1) and/or Ubiquilin 4 (UBQLN4) as well as a method for determining whether a cancer subject is amenable for the treatment with a PARP-1 inhibitor and/or an immune checkpoint inhibitor based on the detection of the mRNA and/or protein expression level of UBQLN1 and/or UBQLN4 in a sample obtained from said cancer subject.

IPC Classes  ?

• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure relates to trapping and manipulating of neutral atoms in optical trapping potentials. In one aspect, an apparatus comprises a trapping laser system and optics for generating an optical trapping lattice at a trapping volume inside a vacuum chamber, wherein the optics for generating the optical trapping lattice are configured to generate, based on the output of the trapping laser system, a single elliptical trapping laser beam that is retroreflected and focused, using a bow-tie configuration, to the trapping volume to generate the optical trapping lattice.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

The present disclosure relates to trapping and manipulating neutral atoms for quantum computing, quantum simulation and metrology. In one aspect a method comprises loading a plurality of neutral atoms into a loading trap array arranged adjacent to or at least partially collocated with a storage trap array, selectively removing neutral atoms in a first electronic state |1> from the storage trap array, determining a trap occupancy of neutral atoms in the storage trap array in a second electronic state |2>, and of neutral atoms in the loading trap array, and moving, based on the determined trap occupancy of the neutral atoms in the storage trap array and in the loading trap array, neutral atoms from the loading trap array to one or more non-occupied trapping sites of the storage trap array. The method may further comprise shelving the neutral atoms in a shelving state.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

The present invention relates to a catalytically active material, the preparation thereof, and the use of the catalytically active material, e.g. in the catalytic oxidation of CO to CO2 or in the catalytic hydrogenation of alkyne. The catalytically active material comprises a support5 comprising a metal oxide, and atomically dispersed noble metal on the surface of the support, wherein the metal oxide is selected from TiO2, CeO2, ZnO, SnO2, Ga2O3, In2O3, ZrO2, and Fe2O3, the noble metal is selected from Pt, Pd, Rh, and Au, and the catalytically active material is obtainable by a method comprising a step of non-thermal plasma treatment in the presence of O2.

IPC Classes  ?

• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• B01J 23/63 - Platinum group metals with rare earths or actinides
• B01J 35/45 - Nanoparticles
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/08 - Heat treatment
• C01B 32/50 - Carbon dioxide
• C07C 5/08 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of carbon-to-carbon triple bonds

Abstract

3113, and further selecting out of these compounds the ones which contain at least a heavy metal for high spin polarization, and sort these selected compounds with increasing spin-orbit-coupling (SOC), which results in a number of compounds which are sorted with increasing catalytic activity.

IPC Classes  ?

• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 11/089 - Alloys
• H01M 4/90 - Selection of catalytic material
• H01M 4/92 - Metals of platinum group

Abstract

The invention is related to a method of using a thermal laser evaporation (TLE) system (100), the system (100) comprising a reaction chamber (10) fillable with a reaction atmosphere (14), one or more sources (30) arranged in the reaction chamber (10), each source (30) comprising a source material (32), and a laser source (50) for providing laser radiation (52) at a surface (34) of the source (30) and thereby evaporating the source material (32). Further, the invention is related to a thermal laser evaporation system (100) comprising a reaction chamber (10) fillable with a reaction atmosphere (14), one or more sources (30) arranged in the reaction chamber (10), each source comprising a source material (32), and coupling means (12) provided by the reaction chamber (10) for coupling laser radiation (52) into the reaction chamber (10) for impinging on a surface (34) of the source (30) and thereby evaporating the source material (32).

IPC Classes  ?

• C23C 16/448 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for generating reactive gas streams, e.g. by evaporation or sublimation of precursor materials
• B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
• B23K 26/073 - Shaping the laser spot
• B23K 26/12 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure
• B23K 26/362 - Laser etching

Abstract

The invention is related to a method of using a thermal laser evaporation (TLE) system (100), the system (100) comprising a reaction chamber (10) fillable with a reaction atmosphere (14), one or more sources (30) arranged in the reaction chamber (10), each source (30) comprising a source material (32), and a laser source (50) for providing laser radiation (52) at a surface (34) of the source (30) and thereby sublimating the source material (32). Further, the invention is related to a thermal laser evaporation system (100) comprising a reaction chamber (10) fillable with a reaction atmosphere (14), one or more sources (30) arranged in the reaction chamber (10), each source comprising a source material (32), and coupling means (12) provided by the reaction chamber (10) for coupling laser radiation (52) into the reaction chamber (10) for impinging on a surface (34) of the source (30) and thereby sublimating the source material (32).

IPC Classes  ?

• C23C 16/448 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for generating reactive gas streams, e.g. by evaporation or sublimation of precursor materials
• B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
• B23K 26/064 - Shaping the laser beam, e.g. by masks or multi-focusing by means of optical elements, e.g. lenses, mirrors or prisms
• B23K 26/067 - Dividing the beam into multiple beams, e.g. multi-focusing
• B23K 26/073 - Shaping the laser spot
• B23K 26/08 - Devices involving relative movement between laser beam and workpiece
• B23K 26/12 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure
• B23K 26/362 - Laser etching

Abstract

The present invention relates to a method for the generation of outer radial glial (oRG) cells of the outer sub-ventricular (oSVZ)-like region in cerebral organoids comprising (a) culturing primate stem cells in a primate stem cell medium until about day 6, thereby inducing the formation of embryonic bodies; (b) culturing the embryonic bodies as obtained in step (a) in a neural induction medium until about day 11, thereby inducing the formation of organoids; wherein an inhibitor of TGF-β, an inhibitor of BMP and an inhibitor of WNT is present from about day 2 until about day 11; (c) embedding the organoids as obtained after steps (a) and (b) and if they display a size of at least 300 μm into a hydrogel that mimics the extracellular matrix (ECM), preferably Matrigel and culturing the organoids in a cerebral differentiation medium at least until about day 40, preferably at least until about day 60 and most preferably at least until about day 80, thereby obtaining cerebral organoids with oRG cells in oSVZ-like regions, wherein the organoids in step (c) are subjected to agitation from about day 15 onward, preferably by using an orbital shaker or a spinning bioreactor; and (d) optionally isolating one or more oRG cells from the oSVZ-like region.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12N 5/0793 - Neurons

Abstract

A method of scattering-type scanning near-field optical microscopy (s-SNOM) comprises placing an s-SNOM tip 11 at a near-field distance from a sample 1 and subjecting the s-SNOM tip 11 to a mechanical oscillation, which provides a primary modulation, illuminating the oscillating s-SNOM tip 11 with a sequence of illumination light pulses, wherein each of the illumination light pulses hits the s-SNOM tip 11 at a specific s-SNOM tip modulation phase φi of the mechanical oscillation, collecting scattering light pulse amplitudes Si, each being created by scattering one of the illumination light pulses at the s-SNOM tip 11, using a scattering light detector device 30, collecting the s-SNOM tip modulation phase i associated to each of the collected scattering light pulse amplitudes Si, using a mechanical oscillation detector device 40, and calculating an s-SNOM near-field signal by demodulating a scattering light function S(φi) of the scattering light pulse amplitudes Si in dependency on the s-SNOM tip modulation phases φi, wherein each of the s-SNOM tip modulation phases pi is obtained by splitting an output signal of the mechanical oscillation detector device 40 into a first output signal portion X and a second output signal portion Y being phaseshifted relative to the first output signal portion X and calculating the s-SNOM tip modulation phase φi of the primary modulation from the first and second output signal portions X, Y. Furthermore, a scanning near-field optical microscopy apparatus 100 is described.

IPC Classes  ?

• G01Q 60/18 - SNOM [Scanning Near-Field Optical Microscopy] or apparatus therefor, e.g. SNOM probes

Abstract

The present invention relates to a temperature control system (10) for adjusting a temperature (60) of a vacuum chamber (102), the temperature control system (10) comprising conduits (20) which can be thermally coupled to a chamber wall (110) of the vacuum chamber (102), a fluid pump (50), temperature adjusting means (30) comprising a heating means (32) or both a heating means (32) and a cooling means (34), and tubing (52) for fluidly connecting said conduits (20), fluid pump (50), and temperature adjusting means (30), respectively. Further, the present invention relates to a vacuum system (100) with a vacuum chamber (102), the vacuum chamber (102) comprising a chamber wall (110) enclosing a vacuum volume (106), a vacuum pump system (104) connected to the vacuum chamber (102) for evacuating the vacuum volume (106), and a temperature control system (10) for adjusting a temperature (60) of a vacuum chamber (102). In addition, the present invention relates to a method of adjusting the temperature (60) of a vacuum chamber (102) of said vacuum system (100).

IPC Classes  ?

• C23C 14/54 - Controlling or regulating the coating process
• C23C 14/28 - Vacuum evaporation by wave energy or particle radiation

Abstract

NicotianaNicotiana tabacum Nicotiana sylvestris Nicotiana sylvestris.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to a compound of general formula (I) The present invention relates to a compound of general formula (I) The present invention relates to a compound of general formula (I) or an enantiomer, diastereomer, stereoisomer, which mediates resistance against leaf- and planthopper pests. The present invention further relates to a method of producing the compound, an enzymatic production method the compound using at least a BBL2 polypeptide, as well as a PPO, AT1, ODC, HPL, PAL, C4H, 4CL, HCT and/or C3H activity. Further envisaged are genetically modified organisms producing the compound, expression cassettes for heterologous expression of the activities, the use of corresponding polypeptides and polynucleotides for the production of the compound, a composition including the compound, as well as uses of the compound for plant protection.

IPC Classes  ?

• C07C 235/78 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
• A01N 37/42 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing within the same carbon skeleton a carboxylic group or a thio-analogue, or a derivative thereof, and a carbon atom having only two bonds to hetero atoms with at the most one bond to halogen, e.g. keto-carboxylic acids
• A01P 15/00 - Biocides for specific purposes not provided for in groups
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/88 - Lyases (4.)
• C12P 13/02 - Amides, e.g. chloramphenicol

Abstract

The present invention relates to a Janus kinase (JAK) inhibitor and to pharmaceutical composition comprising a Janus kinase (JAK) inhibitor, respectively, for use for the treatment of toxic epidermal necrolysis (TEN) and/or Stevens-Johnson-syndrome (SJS) and/or SJS/TEN overlap. The invention further relates to a method for treatment of toxic epidermal necrolysis (TEN) and/or Stevens-Johnson-syndrome (SJS) and/or SJS/TEN overlap comprising application of a Janus kinase (JAK) inhibitor to a patient.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 17/00 - Drugs for dermatological disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed is an optical fiber feedthrough (10) configured to feed through optical fibers (1) between an interior and exterior of evacuable vacuum chamber (30). The feedthrough includes at least one mounting flange (11a, 11b) configured for pressure-tight fastening to vacuum chamber and includes passage openings (12a, 12b) configured for pressure-tightly receiving a respective optical fiber. The passage openings are each provided with a sealing receptacle (13a, 13b) and a sealing element (14a, 14b) arranged therein for pressure-tightly receiving the respective optical fiber. A compression device (15a, 15b) is connected to each mounting flange, which is configured to compress the respective sealing elements axially along the respective passage openings. Also disclosed is an optical fiber assembly (20) including the feedthrough and optical fibers, and a method for passing a plurality of optical fibers between an interior and exterior of an evacuable vacuum chamber using the aforementioned feedthrough.

IPC Classes  ?

• G02B 6/44 - Mechanical structures for providing tensile strength and external protection for fibres, e.g. optical transmission cables

Abstract

Disclosed is a method of manufacturing an optical fiber, the method comprising: providing a fiber manufacturing intermediate product, the fiber manufacturing intermediate product comprising: (i) a hollow core cane comprising a first jacket with a hollow inner structure, wherein a plurality of capillaries are fused to the first jacket within the hollow inner structure; and (ii) a second jacket around the hollow core cane; roughening an outer surface of the second jacket over a portion (310) of the second jacket; coupling an end of the fiber manufacturing intermediate product to a pressure connector (402); and drawing a hollow core photonic crystal fiber from the fiber manufacturing intermediate product.

IPC Classes  ?

• C03B 37/027 - Fibres composed of different sorts of glass, e.g. fibre optics
• C03B 37/012 - Manufacture of preforms for drawing fibres or filaments

Abstract

An apparatus for determining an arrhythmia of a living heart comprises a signal evaluation device receiving a signal representing a present electric activity of the heart, and determining a frequency spectrum of the signal. The apparatus further comprises a pulse generator generating a sequence of electric pulses to be applied to the heart at a pulse repetition frequency that depends on the frequency spectrum and decreases by at least 20% over the sequence.

IPC Classes  ?

• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential
• A61N 1/37 - MonitoringProtecting
• A61N 1/39 - Heart defibrillators

Abstract

A method of manufacturing a preform for use in the manufacturing process of a hollow-core photonic crystal fiber, the method comprising: (i) providing an elongated preform jacket with a hollow inner structure, the elongated preform jacket having a first and second end; (ii) inserting a hollow capillary preform into the hollow inner structure such that the hollow capillary preform is in contact with the hollow inner structure at a contact position and protrudes out of the hollow inner structure at the first end and at the second end; (iii) at the first end, locally heating a protruding portion of the hollow capillary preform; (iv) bending the protruding portion around the first end of the preform jacket; and (v) applying additional heat to a portion of the hollow capillary preform that is bent around the elongated preform jacket to fuse it to an outer surface of the elongated preform jacket.

IPC Classes  ?

• C03B 37/012 - Manufacture of preforms for drawing fibres or filaments
• C03B 37/027 - Fibres composed of different sorts of glass, e.g. fibre optics
• C03B 23/06 - Re-forming tubes or rods by bending
• C03B 23/207 - Uniting glass rods, glass tubes, or hollow glassware

Abstract

In order to map the surface of a macromolecule, at least one fluorescent probe is introduced into a medium in which the macromolecule is embedded or will be embedded. Then, a plurality of spatial positions of the at least one fluorescent probe with regard to the macromolecule are determined via localization of the at least one singularized fluorescent probe with a simple standard deviation of no more than 2 nm. For this purpose, fluorescence light photons emitted by the singularized fluorescent probe are recorded. In addition, a bounding surface bounding the determined spatial positions with regard to the macromolecule is determined; and a three-dimensional map of at least a part of the surface of the macromolecule is generated from the bounding surface.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/1429 - Signal processing
• G01N 15/1434 - Optical arrangements

Abstract

According to a method of manufacturing a magnetic memory device, various types of magnetic memory devices can be manufactured at low cost by manufacturing a plurality of magnetic modules by using a delamination phenomenon of pattern segments and stacking the plurality of magnetic modules to complete a stacked memory device.

IPC Classes  ?

• H10N 50/01 - Manufacture or treatment
• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• H10N 50/10 - Magnetoresistive devices

Abstract

A drug delivery system comprising a liposome having (a) a lipid bilayer enclosing an aqueous volume, wherein the lipid bilayer comprises i) between 30 and 75 mol percent of at least one encapsulating agent; ii) between 1 and 20 mol percent of an acid-cleavable polyethylene glycol conjugated lipid; iii) between 15 and 45 mol percent of at least one fusogenic agent, and (b) a therapeutic agent or a pharmaceutically acceptable salt thereof, encapsulated within the aqueous volume; wherein the encapsulating agent is a cationic lipid and/or a lipidated polypeptide; and wherein the liposome has a Z-Average diameter size range comprised between 20 nm and 200 nm, as determined by dynamic light scattering.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/46 - Hydrolases (3)
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a system (100) for assessing neurocognitive functioning, comprising a task component (101) configured to provide a task, in particular a cognitive task to a user; a capture component (102) configured to capture biomarker data of a biomarker of the user; and a processing component (103) configured to generate a biomarker response profile based on the biomarker data. The present invention further relates to a method for assessing neurocognitive functioning, comprising the steps of providing a task to a user; capturing biomarker data of a biomarker of the user; generating a biomarker response profile based on the biomarker data.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a system (100) for assessing anhedonia, comprising a task component (101) configured to provide a reward task to a user; a capture component (102) configured to capture biomarker data of a biomarker of the user in response to the reward task; and a processing component (103) configured to generate a biomarker response profile based on the biomarker data. The invention further relates to a method for assessing anhedonia, comprising the steps of providing a reward task, capturing biomarker data of a biomarker of the user in response to the reward task; and generating a biomarker response profile based on the biomarker data.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a safety apparatus (100) for monitoring a light path of a laser beam (1) and for interrupting the laser beam (1) in response to an object (2) approaching the laser beam (1), said apparatus comprising: at least one light barrier device (200) having a light source device (210) arranged to generate a safety light field (3) that extends along at least one longitudinal axis z extending in parallel with the light path of the laser beam (1), and having a sensor device (220) which has at least one sensor element (221) and which is arranged to detect the safety light field (3) and to generate a sensor signal (4) that can be varied by means of at least partial covering of the safety light field (3) by the object (2); and an interruption device (300) which is coupled to the at least one light barrier device (200) and which is arranged to interrupt the laser beam (1) according to a change in the sensor signal (4) of the at least one light barrier device (200). The invention also relates to a laser apparatus which is equipped with the safety apparatus (100), to applications of the safety apparatus (100), and to a method for monitoring a light path of a laser beam (1).

IPC Classes  ?

• G02B 26/04 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the intensity of light by periodically varying the intensity of light, e.g. using choppers
• F16P 3/14 - Safety devices acting in conjunction with the control or operation of a machineControl arrangements requiring the simultaneous use of two or more parts of the body with means, e.g. feelers, which in case of the presence of a body part of a person in or near the danger zone influence the control or operation of the machine the means being photocells or other devices sensitive without mechanical contact
• G01J 1/42 - Photometry, e.g. photographic exposure meter using electric radiation detectors

Abstract

The present invention relates to a computer-implemented method of calculating the ranges of concentrations, of fluxes, or of reaction rate constants in a network of chemical reactions.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G06F 17/16 - Matrix or vector computation

Abstract

The invention relates to a method for determining at least one mass (m) that is lifted and/or carried by a user (B), with the aid of a technical device (100), preferably in the form of a smart watch and/or a sports wristband, the technical device (100) having at least one sensor (10) that is configured to measure at least one dynamic motion parameter, wherein sensor signals of the at least one sensor (10), are processed and/or analyzed to determine at least one mass (m) lifted and/or carried by the user (B).

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01L 1/00 - Measuring force or stress, in general

Abstract

The present invention provides a Computer-implemented method for determining a mapping between point patterns and corresponding coordinates in a 2D latent space, the method comprising: - for each of a set of representative point patterns, determining a set of feature vectors, wherein features of the feature vectors represent perceptual properties, - determining a dissimilarity matrix between the feature vectors of each of representative point patterns, and - performing dimensionality reduction using the dissimilarity matrix to determine the mapping from the representative point patterns to the 2D latent space.

IPC Classes  ?

• G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
• G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions

Abstract

A composition comprising (a) a therapeutic agent or a pharmaceutically acceptable salt thereof; (b) a PEG-monoorthoester-lipid; (c) an amphiphilic lipid; (d) a cationic lipid and/or a beta-alanyl-prolyl-cysteine methyl ester; and optionally (e) a steroid and/or a ceramide and/or DOPE. The composition for use as a medicament.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/46 - Hydrolases (3)
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to nanocontainers for the synergistic transport of lipophilic and hydrophilic active ingredients or detection reagents. In particular, the nanocontainers according to the invention offer a possibility for diagnosing and/or treating diseases with combinations of active ingredients (therapy) and detection reagents (diagnostics), which have different solubility properties. The present invention further relates to a method for producing the nanocontainers according to the invention.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/65 - Tetracyclines
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61K 49/00 - Preparations for testing in vivo
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes

Abstract

A method of operating a magnetic memory device includes: (i) applying a first current to a free layer of a magnetic tunnel junction structure, which includes a magnetic translation unit (MTU) extending between a first magnetic pad and a second magnetic pad, and a tunnel barrier layer and a pinned layer stacked on the MTU, so that a multi-domain is established within the MTU, (ii) applying a magnetic field to the free layer so that the magnetization direction of the MTU switches to become anti-parallel to the magnetization directions of the first magnetic pad and the second magnetic pad, (iii) applying a second current to the free layer so that a portion of the multi-domain penetrates into the first magnetic pad, and (iv) applying another magnetic field to the free layer so that the magnetization direction of the first magnetic pad switches.

IPC Classes  ?

• G11C 19/08 - Digital stores in which the information is moved stepwise, e.g. shift registers using magnetic elements using thin films in plane structure
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• H10N 50/10 - Magnetoresistive devices
• H10N 50/80 - Constructional details

Abstract

The present invention relates to an electrode comprising or consisting of an electrocatalyst, the electrocatalyst comprising a metal boride, wherein the metal boride comprises at least one element M1 selected from Ti, Zr and Hf, and at least one element M2 selected from Co, Ni, Ru, Rh, Pd, Ir and Pt; and the metal boride contains more than 10 atomic % of M2. The present invention also provides an electrode obtainable by subjecting the electrode to an electrocatalytic reaction. It also relates to an electrolyzer comprising said electrode. It is also concerned with a method for producing an electrode, and use of an electrode in an electrocatalytic reaction.

IPC Classes  ?

• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• B01J 21/02 - Boron or aluminiumOxides or hydroxides thereof
• C25B 11/047 - Ceramics
• C25B 11/067 - Inorganic compound e.g. ITO, silica or titania
• C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
• H01M 4/90 - Selection of catalytic material
• C01B 35/04 - Metal borides

Abstract

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2 and that have been selected for potent cross-reaction and cross-neutralization between the original Wuhan strain and the Alpha, Beta, Gamma, Delta, and Mu variants of concern.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a method to query a molecular interaction between a first and a second partner moiety, wherein the first partner moiety is associated to a first partial effector sequence, and the second partner moiety is associated to a second partial effector sequence. The first and second partial effector sequences constitute a functional split HaloTag system. The first partner is a peptide sequence encoded by a polynucleotide sequence, and is physically associated with the polynucleotide sequence. The method according to the invention comprises the steps of: a) contacting the first and the second partner moiety in the presence of a HaloTag substrate covalently linked to a separation function; b) separating the first partner moiety being attached to the separation function; c) determining a molecular interaction between the first partner moiety and the second partner moiety by detecting the presence of the polynucleotide sequence.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A three-dimensional arrangement of nanoscopic devices, the arrangement comprises a scaffold structure; and a plurality of nanoscopic devices, the nanoscopic devices being configured to exhibit a nonreciprocal transmission probability of electron quantum wave packets, wherein the nanoscopic devices are attached to the scaffold structure, wherein a majority of the nanoscopic devices are oriented with one and the same transmission direction of higher transmission probability of the electron quantum wave packets.

IPC Classes  ?

• H10N 19/00 - Integrated devices, or assemblies of multiple devices, comprising at least one thermoelectric or thermomagnetic element covered by groups
• H10N 10/01 - Manufacture or treatment
• H10N 10/82 - Interconnections

Abstract

Disclosed is an acoustic trapping assembly (100) comprising a focused ultrasound transducer (102) and a plurality of hollow microrobots (110). The focused ultrasound transducer (102) is configured for generating an acoustic pressure maximum within a focal area (106) of a focused ultrasound beam (104) emitted by the focused ultrasound transducer (102) with the plurality of hollow microrobots (110) being acoustically trapped within the acoustic pressure maximum under fluid flow in a fluidic medium (120). The hollow microrobots (110) comprise solid shells (112) filled with gas.

IPC Classes  ?

• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/50 - Microcapsules

Abstract

The present invention relates to methods and devices for transmitting packets in a data center network (DCN), the data center comprising a multitude of host servers, a multitude of top-of- rack, ToR, switches connected to the host servers and an optical network fabric connected to the multitude of top-of-rack switches, wherein the optical network fabric operates according to a given schedule, wherein the given schedule defines, for each time slice in a sequence of time slices, which pairs of top-of-rack switches are connected by a dedicated optical circuit established by an optical controller of the optical network fabric for said time slice, wherein a top-of- rack switch: synchronizes to another top-of-rack switch; receives a packet at an ingress port; and sends the packet to an egress port. According to the invention, synchronizing comprises sending a synchronization message to said another top-of-rack switch in-band.

IPC Classes  ?

• G06F 1/04 - Generating or distributing clock signals or signals derived directly therefrom
• H04J 3/06 - Synchronising arrangements
• H04Q 11/00 - Selecting arrangements for multiplex systems

Abstract

The present invention relates to a method and system for producing adenosine triphosphate (ATP) through an acid/aldehyde-ATP (AAA) cycle in an electrochemical cell.

Abstract

The present disclosure relates to a device and a method for quantum computing using a plurality of neutral atoms in an array of optical traps, wherein a first internal state of the neutral atoms serves as qubit ground state |o>, and a second internal state serves as qubit excited state |1>. According to the present disclosure, a local single-qubit gate operation on a qubit may be performed comprising locally and selectively illuminating the qubit prepared in a superposition state |s> of qubit ground state |o> and qubit excited state |1> with a qubit addressing laser at a first qubit addressing laser frequency to cause a differential Stark shift for the qubit ground state |o> and the qubit excited state |1>, Further, a local two-qubit gate operation may be performed on a pair of qubits comprising locally and selectively illuminating the pair of qubits prepared in the qubit ground state |o> with the qubit addressing laser at a second qubit addressing laser frequency for coupling the pair of qubits to a Rydberg state |r> of the neutral atoms preferably via a third internal state c> of the neural atoms that can serve as an intermediate state of a two-photon transition from the qubit ground state |o> to the Rydberg state |r>.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present invention relates to polyproline-based block copolymers and compositions thereof, which e.g. are useful for delivering active ingredients, including nucleic acids, and/or imaging agents to target cells or tissues.

IPC Classes  ?

• C08G 69/10 - Alpha-amino-carboxylic acids
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The present invention relates to a modified cell, in particular a modified blood cell, having a cell membrane encapsulating a lumen of the modified cell, wherein a functional lipid is incorporated into the cell membrane, wherein the functional lipid has a bonding site capable of bonding to a molecule having a functional motif, and wherein the bonding site is located on an external surface of the cell membrane. Further, the present invention concerns a pharmaceutical composition, the use of the modified cell and/or the pharmaceutical composition for use as a medicament or as a contrast agent as well as a method of modifying a cell.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/078 - Cells from blood or from the immune system

Abstract

The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease. The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 35/00 - Antineoplastic agents
• C07D 498/08 - Bridged systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

A method of determining nanoparticle properties of nanoparticles (2) included in a sample (1), comprising the steps of collecting sequential frames of images by employing an interferometric microscope device (110), wherein the sample (1) is illuminated with illumination light (3) from a coherent light source device (111) and the images are created by scattering light (4) from the nanoparticles (2) superimposed with non-scattered reference light, said scattering light and reference light having a wavelength larger than a cross-sectional dimension of the nanoparticles (2), tracking the nanoparticles (2) in the sequential frames of images, wherein at least one interferometric point spread function (iPSF) feature of each of the nanoparticles (2) is established and nanoparticle trajectory motion data are determined for each nanoparticle (2), comprising the nanoparticle positions in each frame, for each nanoparticle (2), calculating a nanoparticle size d from the trajectory motion data of the nanoparticle and calculating an interferometric nanoparticle contrast from the at least one iPSF feature of the nanoparticle.

IPC Classes  ?

• G01N 15/1433 - Signal processing using image recognition
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/1434 - Optical arrangements

Abstract

The present invention concerns a lithium metal electrode, in particular for a lithium ion battery, comprising a three-dimensional network of metal fibers, wherein the metal fibers are directly in contact to one another, wherein the metal fibers have a thickness and/or width in the range of 0.25 to 200 μm, and wherein metallic lithium is provided on the surface of the metal fibers of the tree-dimensional network of metal fibers. Further, the present invention concerns a Method of manufacturing a lithium metal electrode, wherein the method comprises the steps of a) providing a three-dimensional network of metal fibers, wherein the metal fibers are directly in contact to one another, wherein the metal fibers have a thickness and/or width in the range of 0.25 to 200 μm; and b) providing a layer of metallic lithium on the fibers of the three-dimensional network of metal fibers.

IPC Classes  ?

• H01M 4/66 - Selection of materials
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/04 - Processes of manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/70 - Carriers or collectors characterised by shape or form
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

A shutter device (100) comprises a backplane (10), a front cap (20), and a single shutter blade (30) mounted between the backplane (10) and the front cap (20), wherein the shutter blade (30) is connectable with a drive mechanism and movable between an open state and a closed state.

IPC Classes  ?

• G02B 26/02 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the intensity of light
• G02B 21/16 - Microscopes adapted for ultraviolet illumination
• G02B 21/00 - Microscopes

Abstract

The present invention relates to VHH antibodies that specifically bind to components of nuclear pore complexes of human cells and other species. Further, the present invention relates to the labelling of VHH antibodies through maleimide chemistry and ectopic cysteine residues. Further, the present invention relates to a method for forming a stabilizing, structural disulfide bond in initially reduced VHH antibodies.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention relates to a method for increasing the frequency of meiotic crossover in a plant, plant part, plant tissue culture or plant cell comprising inhibiting in said plant, plant part, plant tissue culture or plant cell the expression and/or the function of the proteins ZYP1 and RECQ4. The present invention furthermore relates to a plant, plant part, plant tissue culture or plant cell, wherein the expression and/or the function of the proteins ZYP1 and RECQ4 is inhibited.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to a method for identifying and separating a specific component of interest from a plurality of components, the method comprises the steps of: A) providing a dispersion comprising the plurality of components, optionally enclosed in compartments, and a photoresist, wherein among the plurality of components at least one portion shows a factor of interest; B) scanning of the dispersion for at least one factor of interest to identify said at least one portion among the plurality of components or optionally of the compartments and selecting those components or optionally compartments of interest and attributing a location to the components or optionally compartments of interest within the dispersion; C) applying a light to at least one part of the dispersion for curing said photoresist either attributed to the components of interest or not attributed to the components of interest; and D) separating a component from parts of the dispersion with cured photoresist from components from other parts of the dispersion with uncured photoresist. Further, the present invention relates to a device configured to carry out the method according to any one of the preceding claims.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/1429 - Signal processing
• G01N 15/1433 - Signal processing using image recognition
• G01N 15/1434 - Optical arrangements
• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 15/10 - Investigating individual particles
• C08F 299/02 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers from unsaturated polycondensates

Abstract

A method for fabricating a magnetic device comprises providing a layer stack, the layer stack comprising a substrate, a first ferromagnetic layer disposed above the substrate, the first ferromagnetic layer comprising a uniaxial magnetic anisotropy including an easy axis, a non-magnetic layer disposed on the first ferromagnetic layer, a second ferromagnetic layer disposed on the non-magnetic layer, the second ferromagnetic layer comprising a unidirectional anisotropy, and an antiferromagnetic layer disposed on the second ferromagnetic layer, the antiferromagnetic layer comprising a Néel temperature TN; heating the layer stack above the Néel temperature TN of the antiferromagnetic layer; applying a magnetic field HCL to the layer stack, the magnetic field HCL comprising a magnetic field direction having an arbitrary angle with respect to the easy axis; cooling the layer stack below the Néel temperature TN of the antiferromagnetic layer with the magnetic field HCL applied; and removing the magnetic field HCL.

IPC Classes  ?

• H10N 50/01 - Manufacture or treatment
• H10N 50/10 - Magnetoresistive devices
• H10N 50/85 - Materials of the active region
• H10N 60/01 - Manufacture or treatment
• H10N 60/85 - Superconducting active materials

Abstract

The present invention relates to a source (100) for providing a directed flow of source material (80) thermally evaporated and/or sublimated by a laser beam (68) and emerging in a flow direction (84) from the source (100) at a flow opening (90) of a source chamber (10) of the source (100). Further, the present invention relates to a deposition system (200) for coating of a substrate (222), comprising a reaction chamber (210) enclosing a reaction volume (212), a substrate arrangement means (220) for arranging the substrate (222) to be coated within the reaction volume (212), and said source (100) for providing a directed flow (82) of evaporated and/or sublimated source material (80), wherein the reaction chamber (210) comprises a source opening (230) in a reaction chamber wall (216) of the reaction chamber (210) such that a line of sight (240) between the source opening (230) and the substrate (222) to be coated is free, and wherein the source (100) is sealingly arranged with its flow opening (90) at the source opening (230).

IPC Classes  ?

• C23C 14/28 - Vacuum evaporation by wave energy or particle radiation
• C23C 14/52 - Means for observation of the coating process
• C23C 14/24 - Vacuum evaporation
• C23C 14/54 - Controlling or regulating the coating process
• C23C 14/56 - Apparatus specially adapted for continuous coatingArrangements for maintaining the vacuum, e.g. vacuum locks
• C30B 23/00 - Single-crystal growth by condensing evaporated or sublimed materials

Abstract

The present invention relates to a method for finding global regulators in order to induce or increase production of target secondary metabolites. The method comprises providing a bacterium indicator strain producing two fluorescent reporter signals under the same control of two different biosynthetic gene clusters (BGC), preferably highly expressed BGC, performing random mutagenesis in said bacterium indicator strain, and selecting mutant bacteria not producing said reporter signals. The invention also relates to a method to activate the production of target secondary metabolites, and to a CRISPR/Cas based single plasmid to delete or inactivate a global regulator and/or activate a BGC. Finally, the inventive method can be performed in high-throughput format allowing to speed-up the procedure.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12N 15/67 - General methods for enhancing the expression
• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The invention relates to a flange (10) made of an aluminum alloy, wherein the flange (10) is arranged sealedly or can be arranged sealedly at an opening (104) in a chamber wall (102) of a vacuum and/or reaction chamber (100), and wherein the flange (10) has a peripheral and planar sealing surface (20) for sealing the opening (104) in the vacuum and/or reaction chamber (100) with respect to the surroundings, which sealing surface is adjoined by a cutting edge (30) for a knife-edge seal (40). The invention also relates to a flanged joint (50) comprising a first flange element (52), a second flange element (54), a sealing ring (60), and a clamping device (70), wherein the first flange element (52) and the second second flange element (54) each have a cutting edge (30) for a knife-edge seal (40), wherein the sealing ring (60) is made of a softer material than the cutting edges (30) and can be arranged between the first flange element (52) and the second second flange element (54), and, in order to seal the flanged joint (50), the first flange element (52) and the second flange element (54) can be pressed against one another by means of the clamping device (70), so that the cutting edge (30) of the first flange element (52) and the cutting edge (30) of the second flange element (54) are pressed into the sealing ring (6) from opposing sides. The invention also relates to a vacuum and/or reaction chamber (100) having a chamber wall (102) and an opening (104) in the chamber wall (102), wherein the vacuum and/or reaction chamber (100) also has a flange (10) of this kind for the opening (104), wherein the flange (10) is arranged sealedly at the opening (104). The invention also relates to a system (200) for thermal laser epitaxy (TLE), comprising at least one vacuum and/or reaction chamber (100) of this kind, wherein the vacuum and/or reaction chamber (100) has a chamber wall (102) having one or more openings (104) at each of which one flange (10) is arranged.

IPC Classes  ?

• F16L 23/032 - Flanged joints the flanges being connected by members tensioned axially characterised by the shape or composition of the flanges
• F16L 23/20 - Flanged joints characterised by the sealing means the sealing means being rings made exclusively of metal
• C22C 21/06 - Alloys based on aluminium with magnesium as the next major constituent
• C22C 21/12 - Alloys based on aluminium with copper as the next major constituent
• F16L 55/115 - Caps
• F16J 15/08 - Sealings between relatively-stationary surfaces with solid packing compressed between sealing surfaces with exclusively metal packing

Abstract

The present invention relates to racetrack memory array devices, and more specifically, to a manufacturing method of racetrack memory arrays with integrated magnetic tunnel junction for read/write.

IPC Classes  ?

• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• H10N 50/01 - Manufacture or treatment
• H10N 50/10 - Magnetoresistive devices
• H10N 50/85 - Materials of the active region

Abstract

The present invention relates to a method for non-invasive production of defined structures inside compartments, wherein the method comprises the steps of: providing a compartment having an inside filled with a liquid, comprising a photoresist, and applying light to the inside of the compartment including the photoresist, wherein the light has a focal point inside the compartment and initiates a chemical reaction of the photoresist at the focal point, creating a defined structure. Further, the present invention relates to a compartment, having an inside, surrounded by a compartment wall, wherein the compartment comprises a defined structure obtainable by a method according to any one of the preceding claims.

IPC Classes  ?

• G03F 7/20 - ExposureApparatus therefor
• B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
• B29K 71/00 - Use of polyethers as moulding material
• B33Y 10/00 - Processes of additive manufacturing
• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
• G03F 7/029 - Inorganic compoundsOnium compoundsOrganic compounds having hetero atoms other than oxygen, nitrogen or sulfur

Abstract

The present invention provides a Glycolyl-CoA Carboxylase (GCC), wherein said GCC is characterized in that: it comprises an amino acid sequence having at least 60 % sequence identity to SEQ ID NO: 1, and it has one or more amino acid substitutions, deletions or insertions at a position selected from the group consisting of positions 20 and 100 in the amino acid sequence shown in SEQ ID NO: 1 or at a position corresponding to any of these positions, preferably wherein the GCC has an improved activity over a reference GCC, preferably wherein the reference GCC comprises the amino acid sequence of SEQ ID NO: 1.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

The present invention relates to a method for genetically engineering the genome of phages at a target locus by CRISPR-Cas, where the phases the genome of which is to be genetically engineered are comprises in a bacterial cell, a L-form bacterium, a cell-free transcription-translation system (TXTL) system or a bacterial cell lysate expressing a Tet-like protein.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

In a first aspect the present invention relates to a system for continuous measurement of osmolarity in situ. Said system comprises phase-separated membrane enclosed compartment as the sensor in osmolarity; detection means: a processing unit, and, optionally, an output unit of absolute or relative osmolarity and/or osmolarity changes. Further, the use of the phase-separated membrane enclosed compartment, whereby the membrane is permeable to a solvent and non-permeable to the osmotically active substance for non-invasive osmolarity measurement in a liquid system is described. In addition, a method for determining osmolarity and/or osmolarity change in a system is provided including the phase-separated membrane enclosed compartment, whereby the membrane is a permeable to a solvent and non-permeable to the osmotically active substance. Finally, a set of phase-separated membrane enclosed compartment, whereby the membrane is permeable to a solvent and non-permeable to the osmotically active substance, having predetermined different inner osmolarities useful for calibrations of osmolarity of an osmolarity measuring system is disclosed.

IPC Classes  ?

• G01N 13/04 - Investigating osmotic effects

Abstract

The invention relates to ancestral citrate synthase proteins which are capable of forming at least 3 different complexation states simultaneously. The invention further relates to compositions comprising the ancestral citrate synthase proteins, use of the ancestral citrate synthase proteins or compositions, nucleic acids encoding the ancestral citrate synthase proteins, and methods of purifying the ancestral citrate synthase proteins.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to a method for manipulating domain walls (DWs) in a magnetic ribbon, which method comprises imposing a curvilinear 3D structure upon at least one region of the magnetic ribbon. Moreover, the invention relates to a curvilinear 3D magnetic ribbon, which extends between two ends and which has at least one twisted region between its two ends wherein the twisted region exhibits an absolute torsion angle over its length of 1-70°, and the torsion angle has an increase per unit length of 0.5-60°.

IPC Classes  ?

• H10N 50/00 - Galvanomagnetic devices
• H10N 50/01 - Manufacture or treatment
• H10N 50/80 - Constructional details
• H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties

Abstract

The present disclosure relates to an electronic tag for behavioural monitoring of animals, the electronic tag comprising a microprocessor and at least one sensor. The electronic tag is configured to obtain, via the at least one sensor, movement data of an animal to which the electronic tag is attached and to determine, based on the obtained movement data, a behaviour of the animal. The disclosure further encompasses a corresponding method as well as an ear tag.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry
• A01K 11/00 - Marking of animals
• A01K 27/00 - Leads or collars, e.g. for dogs

Abstract

A method sequentially transmits signals of polarization states of light through an optical fiber. The optical fiber being a polarization preserving optical fiber. For each signal, a signal state is prepared as one out of a set of at least two non-orthogonal polarization states of light and sent through the optical fiber from a sender site to a receiver site. A method for quantum key distribution using polarization states of light is performed, wherein an alphabet of elementary information values is encoded in a set of non-orthogonal polarization states of light such that each elementary information value is represented by at least one of the polarization states. A classical message of elementary information values out of the alphabet is prepared, wherein the respective polarization states corresponding to the elementary information values of the classical message are prepared at a sender site as signal states.

IPC Classes  ?

• H04B 10/532 - Polarisation modulation
• H04B 10/25 - Arrangements specific to fibre transmission
• H04B 10/70 - Photonic quantum communication

Abstract

The present invention relates to a method for the diagnosis and/or classification of a disease in a subject based on the genetic and/or epigenetic information of a sample obtained from the subject, the method comprising the steps of: a) providing data from said sample, wherein said data comprises genetic and/or epigenetic information of a random subset of genomic positions: b) assigning said sample to a sample class based on genetic and/or epigenetic information of said random subset of genomic positions by employing a computational model, which discriminates a plurality of sample classes based on genetic and/or epigenetic information of a set of genomic positions comprising said random subset, wherein the computational model has been trained with pre-determined genetic and/or epigenetic information obtained from a plurality of pre-classified samples of known diseases and wherein said computational model processes the genetic and/or epigenetic information of a genomic position of said random subset independently of the genetic and/or epigenetic information of another genomic position of said random subset, wherein said computational model is preferably in the form of a linear classifier with independent feature sampling.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 5/20 - Probabilistic models
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 30/10 - Sequence alignmentHomology search
• G16B 40/20 - Supervised data analysis

Abstract

The invention relates to an optical component comprising a metasurface, wherein the metasurface comprises a repeating pattern of unit cells, wherein each unit cell comprises at least two different scattering structures, wherein first scattering structures are at least partially contacting a first substance having a first refractive index and second scattering structures are at least partially contacting a second substance, which differs from the first substance, wherein the second substance provides a refractive index which is variable depending on an electrical control signal, wherein a plurality of pairs of first scattering structures contacting the first substance and second scattering structures contacting the second substance are arranged row-wise on electrodes, wherein electrodes supporting neighboring rows of pairs of first and second scattering structures are electrically separated from each other, and a LIDAR system comprising such an optical component. Furthermore, the invention relates to a method for amending a deflection angle of such an optical component.

IPC Classes  ?

• G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection

Abstract

The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections. The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 515/04 - Ortho-condensed systems

Abstract

A confocal microscopy apparatus 100 for imaging a sample 2 under investigation by chromatic confocal microscopy comprises an illumination source device 10 being arranged for creating illumination light 1 having an illumination spectrum covering a plurality of illumination wavelengths, a focusing device 40 including at least one focusing lens 41 being configured for focusing the illumination light 1 along an imaging axis z into a plurality of wavelength-dependent focal planes in an axial imaging range of a sample 2 to be investigated, wherein the at least one focusing lens 41 is further arranged for collecting scattering light 3 created in the focal planes of the sample 2, and a detector device 50 being arranged for spectrally resolved detecting of the scattering light 3, wherein the at least one focusing lens 41 is made of a dispersive focusing lens 41 material with an Abbe number equal to or below 8, like e. g. ZnSe. Furthermore, a confocal microscopy method for imaging a sample 2 to be investigated by chromatic confocal microscopy is described.

IPC Classes  ?

• G02B 21/00 - Microscopes

Abstract

The invention relates to novel caging-group-free photactivatable fluorescent dyes having the structural formula (I) as well as to the corresponding photoactivated fluorescent dyes having the structural formula (II). The invention further relates to the use of the photoactivatable compounds as such or after photoactivation, in particular as fluorescent tags, analytical reagents and labels in optical microscopy, imaging techniques, protein tracking, nucleic acid labeling, glycan analysis, capillary electrophoresis, flow cytometry or as a component of biosensors, or as analytical tools or reporters in microfluidic devices or nanofluidic circuitry. The invention relates to novel caging-group-free photactivatable fluorescent dyes having the structural formula (I) as well as to the corresponding photoactivated fluorescent dyes having the structural formula (II). The invention further relates to the use of the photoactivatable compounds as such or after photoactivation, in particular as fluorescent tags, analytical reagents and labels in optical microscopy, imaging techniques, protein tracking, nucleic acid labeling, glycan analysis, capillary electrophoresis, flow cytometry or as a component of biosensors, or as analytical tools or reporters in microfluidic devices or nanofluidic circuitry.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to self-assembling peptide amphiphiles consisting of a non-self-assembling peptide moiety having a positive net charge under physiological pH, and a hydrophobic moiety covalently coupled to the peptide moiety, wherein the peptide moiety is composed of a positively charged peptide part and a β-sheet forming peptide part, wherein the hydrophobic moiety is covalently coupled to the β-sheet forming peptide part, wherein the peptide amphiphiles self-assemble into fibrils and form μm-sized aggregates in aqueous medium, and wherein the fibrils are efficiently degradable in cells. The peptide amphiphiles of the present invention are useful as viral transduction enhancers for retroviral gene delivery into cells. Thus, the present invention further relates to the use of peptide amphiphiles as retroviral transduction enhancers in retroviral gene delivery into cells, and to methods for retroviral gene delivery into cells in presence of peptide amphiphiles.

IPC Classes  ?

• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present invention relates to an in vitro bioassay to identify glutamine synthetase activators and inhibitors on the basis of one or more glutamine markers such as citrate, a metabolite derived from the mevalonate pathway, a glutamine responsive mRNA or proteins, such as HMGCR or SREBP2. Disclosed herein are also glutamine synthetase activators and inhibitors identified by the inventive method for use to stimulate or inhibit the synthesis of a metabolite derived from the mevalonate pathway, such as cholesterol, and to treat a disease associated with deregulated levels of said metabolite, such as cancer.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to improved methods for obtaining purified contrast agents that are suitable for magnetic resonance imaging. The contrast agents are prepared by a method such dynamic nuclear polarization (DNP), hydrogenative parahydrogen induced polarization (PHIP), or Signal Amplification By Reversible Exchange (SABRE). High degrees of purity are achieved by performing an evaporation step to separate a signal enhanced precursor or the contrast agent from a metal catalyst or a source of radicals.

IPC Classes  ?

• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations